Uma Mahadevan MD, AGAF
Professor of Medicine at University of California, San FranciscoUSA
Rupert Leong MBBS (UWA), FRACP, MD, AGAF
Clinical Professor of Medicine at University of Sydney and UNSWSydney, Australia
Shu-Chen Wei MD, PhD
ProfessorNational Taiwan University Hospital & College of Medicine
The agenda for this live webinar includes two 40-minutes presentations and two 15-minute panel discussions moderated by Prof. Shu-Chen Wei with Prof. Rupert Leong and Prof. Uma Mahadevan.
Agenda (GMT+8):
11:05 – 11:05 : Opening and Introduction
11:05 – 11:45 : Lecture 1 – Advances in Diagnosis and Management of Colonic Dysplasia in IBD
11:45 – 12:00 : Panel Discussion / Question & Answers
12:00 – 12:45 : Lecture 2 – IBD Management in Pregnancy
12:45 – 13:00 : Panel Discussion / Question & Answer
Lecture 1 – Advances in Diagnosis and Management of Colonic Dysplasia in IBD
(Speaker: Professor Rupert Leong)
Clinicians treating inflammatory bowel disease (IBD) are increasingly coming across patients with a current or previous history of malignancies. With increasing and earlier use of immunosuppression and biologics in IBD patients, the question arises whether these treatments further increase the risk of new or recurrent cancers.
In addition to non-intestinal cancers, IBD patients with chronic colonic inflammation have an increased risk of developing intestinal cancers such as colitis-associated dysplasia. Unlike in sporadic CRC in which dysplastic adenomas begin as raised polypoid lesions, dysplasia in IBD can indistinct from surrounding mucosa, making it "invisible" to the endoscopist.
The evolution of newer treatment paradigms focusing on achievement of deep remission and even mucosal healing in IBD has resulted in an increase in the use of immunosuppressive agents and biologics alone, or in combination, in IBD patients. While these treatments have significant efficacy data, the data on safety, particularly in relation to cancer risks, are limited because patients with active cancers or those who had a history of cancer in the preceding 5 to 10 years are excluded from randomized controlled trials. Hence, the data in relation to issues around cancer and IBD will only come from long-term observational studies and registries.
In this presentation, we will review the cancer risks for existing IBD therapies, treatment recommendation for patient with active cancer or history of cancer and discuss the evidence on chemoprevention and screening for dysplasia/colorectal cancer.
Lecture 2 – IBD Management in Pregnancy
(Speaker: Professor Uma Mahadevan)
Inflammatory bowel disease (IBD) is frequently diagnosed in women of childbearing age. The course of IBD is closely related to pregnancy outcomes with poorly controlled IBD increasing the risk of prematurity, low weight for gestation, and fetal loss.
As such, women with IBD face complex decision making weighing the risks of active disease versus those of medical treatments.
With the recent widely use of Advanced therapies (Biologics and small molecules) in management of IBD, it becomes increasing important to gain an understanding of the safety of these medications on pregnancy and how we should be managing pregnant IBD patients when considering issues surrounding dose optimization, management of flares during pregnancy and whether medication should be discontinued.
In this presentation, we will learn about how to manage IBD patients during Pregnancy and lactation. In addition, reviewing the most up to date evidence on the safety of various advanced therapies in the management of pregnant women with IBD.
Prof. Uma Mahadevan completed a medical degree at the State University of New York in Brooklyn. She completed residency in internal medicine at Mount Sinai Medical Center in New York, a fellowship in gastroenterology at the University of California, San Francisco (UCSF) and a fellowship in inflammatory bowel disease (IBD) at the Mayo Clinic in Rochester, Minnesota. Dr. Mahadevan currently serves as Professor of Medicine at UCSF, Co-Director of the UCSF Center for Colitis and Crohn’s Disease and Director of the IBD Fellowship. She is the Ambulatory Clinical Services Chief for Gastroenterology.
Prof. Mahadevan specializes in the treatment of ulcerative colitis, Crohn’s disease, and pouchitis. She has a particular interest in pregnancy and fertility in IBD, nutritional therapies for IBD, as well as in clinical trials of experimental therapy for both ulcerative colitis and Crohn’s disease. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO), clinical trials in biologic therapy for IBD, and microbiome, environmental and dietary changes among patients with IBD.
Prof. Rupert Leong is a Senior Staff Specialist gastroenterologist, Director of Endoscopy and Head of the Inflammatory Bowel Disease Service at Concord Hospital, Clinical Professor of Medicine at University of Sydney and UNSW, and founding director of IBD Sydney, Australia.
He has an international reputation for the management of inflammatory bowel diseases. Prof. Leong has made a substantial contribution to research with over 150 high-quality scientific journals publications.
Prof. Leong was awarded the American Gastroenterological Association Fellowship by invitation on the basis of research excellence in 2012 and the UNSW Paper of the Year Prize in 2015.
Prof. Shu-Chen Wei is a professor of Medicine at National Taiwan University Hospital and College of Medicine.
Prof. Wei graduated from Chung- Shan Medical University was ranked as the top resident at National Taiwan University during her residency training. Professor Wei was a Research fellow at the GI Unit & CSIBD (Center for Study of Inflammatory Bowel Disease) at Massachusetts General Hospital at Boston USA. She was awarded the young physician award under World Congress of Gastroenterology and nominated as Best Attending physician at National Taiwan University Hospital. As an international expert in the field of inflammatory bowel disease who have contributed substantially in IBD research, she has over 100s of publications.
Prof. Wei is actively involved in leading the Taiwan Society of Inflammatory Bowel Disease (TSIBD) to develop the consensus guideline in the management of IBD. Professor Wei is also heavily involved in TSIBD registry study founded under TSIBD to help provide a platform for physicians to mine evidence-based insight that can help to improve patient care.
To access this presentation, please login and click on the 'ENROLL TO WATCH' blue button by the right, on this page. To create a new account, please click here.
